Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways without systematic methodology
PubMed 39412581 · doi:10.1007/s43440-024-00660-y
What was done
This narrative mini-review summarized published literature examining the mechanism of action of psilocybin, focusing on its interactions with 5-HT2A receptors, extracellular glutamate levels in the frontal cortex and hippocampus, downstream GABAergic neurotransmission, and neuroplasticity in depression and related neuropsychiatric disorders.
What was found
The abstract reports no quantitative data or numerical outcomes. It describes a mechanistic cascade wherein psilocybin acts as an agonist at 5-HT2A receptors on cortical pyramidal cells, increasing extracellular glutamate in the frontal cortex and hippocampus. This prefrontal glutamate release increases GABAergic interneuron activity and downstream GABA release, a pathway proposed to promote neuroplasticity and antidepressant efficacy.
Why it matters
Clarifying downstream glutamatergic and GABAergic signaling cascades helps explain how 5-HT2A receptor agonism translates into rapid neuroplastic changes and therapeutic antidepressant effects.
Limits
This is an unsystematic narrative mini-review without systematic search criteria, quality appraisal, or meta-analytic pooling. The abstract provides no primary data, sample sizes, or quantitative effect estimates, and the proposed mechanistic pathway is largely derived from preclinical models.
Cited by
- supports The downstream neurochemical effects of classic hallucinogens like psilocybin are mediated through the glutamate system.